OBJECTIVES: HIV-associated brain injury persists despite combination antiretroviral therapy, but contributing factors remain poorly understood. We postulated that inflammation-associated biomarkers will be associated with cerebral injury on proton magnetic resonance spectroscopy in chronically HIV-infected subjects. METHODS: Five biomarkers were measured in 197 HIV-infected subjects: soluble CD14, MCP-1, IP-10, MIP-1β, and fractalkine. Levels of N-acetyl aspartate (NAA), Choline (Cho), Myoinositol (MI), Glutamate + Glutamine (Glx), and Creatine (Cr) were acquired in the midfrontal cortex (MFC), frontal white matter, and basal ganglia (BG). Predictive models were built through linear regression, and the best models were chosen using the Akaike Information Criterion. RESULTS: Increases in plasma or CSF MCP-1 were associated with lower NAA/Cr in the MFC and BG, whereas metabolite changes in the frontal white matter for NAA/Cr, GlxCr, and Cho/Cr were explained almost exclusively by a single factor, sCD14. Plasma and CSF levels of this factor were also significantly associated with Glx/Cr in MFC and BG. Higher CSF FKN was associated with higher NAA/Cr in BG. Best predictors for higher Cho/Cr in BG and MFC were CSF sCD14 and CSF MIP-1β. Plasma and CSF IP-10 were only associated with Cho/Cr in MFC. Of the 3 models that simultaneously accounted for both plasma and CSF, there were more associations between CSF biomarkers and magnetic resonance spectroscopy metabolites. CONCLUSIONS: Markers of inflammation and immune activation, in particular MCP-1 and sCD14, predominantly reflecting CNS sources, contribute to the persistence of brain injury in a metabolite and region-dependent manner in chronically HIV-infected patients on stable combination antiretroviral therapy.
OBJECTIVES: HIV-associated brain injury persists despite combination antiretroviral therapy, but contributing factors remain poorly understood. We postulated that inflammation-associated biomarkers will be associated with cerebral injury on proton magnetic resonance spectroscopy in chronically HIV-infected subjects. METHODS: Five biomarkers were measured in 197 HIV-infected subjects: soluble CD14, MCP-1, IP-10, MIP-1β, and fractalkine. Levels of N-acetyl aspartate (NAA), Choline (Cho), Myoinositol (MI), Glutamate + Glutamine (Glx), and Creatine (Cr) were acquired in the midfrontal cortex (MFC), frontal white matter, and basal ganglia (BG). Predictive models were built through linear regression, and the best models were chosen using the Akaike Information Criterion. RESULTS: Increases in plasma or CSFMCP-1 were associated with lower NAA/Cr in the MFC and BG, whereas metabolite changes in the frontal white matter for NAA/Cr, GlxCr, and Cho/Cr were explained almost exclusively by a single factor, sCD14. Plasma and CSF levels of this factor were also significantly associated with Glx/Cr in MFC and BG. Higher CSFFKN was associated with higher NAA/Cr in BG. Best predictors for higher Cho/Cr in BG and MFC were CSF sCD14 and CSF MIP-1β. Plasma and CSFIP-10 were only associated with Cho/Cr in MFC. Of the 3 models that simultaneously accounted for both plasma and CSF, there were more associations between CSF biomarkers and magnetic resonance spectroscopy metabolites. CONCLUSIONS: Markers of inflammation and immune activation, in particular MCP-1 and sCD14, predominantly reflecting CNS sources, contribute to the persistence of brain injury in a metabolite and region-dependent manner in chronically HIV-infectedpatients on stable combination antiretroviral therapy.
Authors: Ned Sacktor; Richard L Skolasky; Thomas Ernst; Xiangling Mao; Ola Selnes; Martin G Pomper; Linda Chang; Kai Zhong; Dikoma C Shungu; Karen Marder; Dean Shibata; Giovanni Schifitto; Linda Bobo; Peter B Barker Journal: J Magn Reson Imaging Date: 2005-04 Impact factor: 4.813
Authors: Kevin R Robertson; Marlene Smurzynski; Thomas D Parsons; Kunling Wu; Ronald J Bosch; Julia Wu; Justin C McArthur; Ann C Collier; Scott R Evans; Ron J Ellis Journal: AIDS Date: 2007-09-12 Impact factor: 4.177
Authors: Thomas D Marcotte; Reena Deutsch; Benedict Daniel Michael; Donald Franklin; Debra Rosario Cookson; Ajay R Bharti; Igor Grant; Scott L Letendre Journal: J Neuroimmune Pharmacol Date: 2013-10-08 Impact factor: 4.147
Authors: Xue Hua; Christina P Boyle; Jaroslaw Harezlak; David F Tate; Constantin T Yiannoutsos; Ron Cohen; Giovanni Schifitto; Assawin Gongvatana; Jianhui Zhong; Tong Zhu; Michael J Taylor; Thomas B Campbell; Eric S Daar; Jeffry R Alger; Elyse Singer; Steve Buchthal; Arthur W Toga; Bradford Navia; Paul M Thompson Journal: Neuroimage Clin Date: 2013-08-03 Impact factor: 4.881
Authors: Michael D Rizzo; Robert B Crawford; Anthony Bach; Sera Sermet; Andrea Amalfitano; Norbert E Kaminski Journal: J Neuroimmunol Date: 2019-05-20 Impact factor: 3.478
Authors: Mike Veenstra; Dionna W Williams; Tina M Calderon; Kathryn Anastos; Susan Morgello; Joan W Berman Journal: J Leukoc Biol Date: 2017-07-28 Impact factor: 4.962
Authors: Talia M Nir; Neda Jahanshad; Christopher R K Ching; Ronald A Cohen; Jaroslaw Harezlak; Giovanni Schifitto; Hei Y Lam; Xue Hua; Jianhui Zhong; Tong Zhu; Michael J Taylor; Thomas B Campbell; Eric S Daar; Elyse J Singer; Jeffry R Alger; Paul M Thompson; Bradford A Navia Journal: J Neurovirol Date: 2019-02-14 Impact factor: 2.643
Authors: Ajay R Bharti; Allen McCutchan; Reena Deutsch; Davey M Smith; Ronald J Ellis; Mariana Cherner; Steven P Woods; Robert K Heaton; Igor Grant; Scott L Letendre Journal: Clin Infect Dis Date: 2016-10-28 Impact factor: 9.079
Authors: Michael D Rizzo; Joseph E Henriquez; Lance K Blevins; Anthony Bach; Robert B Crawford; Norbert E Kaminski Journal: J Neuroimmune Pharmacol Date: 2020-05-14 Impact factor: 4.147
Authors: Meghan E Fitzpatrick; Mehdi Nouraie; Matthew R Gingo; Danielle Camp; Cathy J Kessinger; James B Sincebaugh; Andrew Clarke; John W Ries; Eric C Kleerup; Lawrence Kingsley; Alison Morris Journal: AIDS Date: 2016-06-01 Impact factor: 4.177